Les patients avec des maladies rénales préexistantes ou ceux recevant d'autres médicaments néphrotoxiques sont à risque.
Risque médicalComplicationsMaladies rénales
Facteurs de risque
5
#1
Quels facteurs augmentent le risque d'infections résistantes ?
L'utilisation excessive d'antibiotiques, l'hospitalisation prolongée et les soins intensifs augmentent le risque.
Facteurs de risqueInfections résistantesAntibiotiques
#2
Les personnes âgées sont-elles plus à risque ?
Oui, les personnes âgées ont un système immunitaire affaibli, ce qui les rend plus vulnérables.
Personnes âgéesSystème immunitaireVulnérabilité
#3
Les patients immunodéprimés sont-ils à risque ?
Oui, les patients immunodéprimés sont plus susceptibles de développer des infections graves.
ImmunodépressionInfections gravesFacteurs de risque
#4
Comment le diabète influence-t-il le risque d'infection ?
Le diabète peut altérer la réponse immunitaire, augmentant ainsi le risque d'infections bactériennes.
DiabèteInfections bactériennesRéponse immunitaire
#5
Les interventions chirurgicales augmentent-elles le risque d'infection ?
Oui, les interventions chirurgicales peuvent introduire des bactéries et augmenter le risque d'infection.
Interventions chirurgicalesInfectionsFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Polymyxine B : Questions médicales les plus fréquentes",
"headline": "Polymyxine B : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Polymyxine B : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-26",
"dateModified": "2024-12-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Polymyxine B"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Polymyxines",
"url": "https://recherchemedicale.com/mesh/D011113",
"about": {
"@type": "MedicalCondition",
"name": "Polymyxines",
"code": {
"@type": "MedicalCode",
"code": "D011113",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.695.054.600"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Polymyxine B",
"alternateName": "Polymyxin B",
"code": {
"@type": "MedicalCode",
"code": "D011112",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xin Li",
"url": "https://recherchemedicale.com/author/Xin%20Li",
"affiliation": {
"@type": "Organization",
"name": "The Third Hospital of Changsha, Changsha, Hunan, PR China; Institute of Clinical Application of Antibiotics, Changsha, Hunan, PR China. Electronic address: xin-li@cssdsyy.com."
}
},
{
"@type": "Person",
"name": "Jian Li",
"url": "https://recherchemedicale.com/author/Jian%20Li",
"affiliation": {
"@type": "Organization",
"name": "Monash Biomedicine Discovery Institute, Department of Microbiology, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia Jian.Li@monash.edu Tony.Velkov@unimelb.edu.au."
}
},
{
"@type": "Person",
"name": "Tony Velkov",
"url": "https://recherchemedicale.com/author/Tony%20Velkov",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia Jian.Li@monash.edu Tony.Velkov@unimelb.edu.au."
}
},
{
"@type": "Person",
"name": "Man Huang",
"url": "https://recherchemedicale.com/author/Man%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Department of General Intensive Care Unit, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China."
}
},
{
"@type": "Person",
"name": "Maytham Hussein",
"url": "https://recherchemedicale.com/author/Maytham%20Hussein",
"affiliation": {
"@type": "Organization",
"name": "Monash Biomedicine Discovery Institute, Department of Microbiology, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Evaluation of the in vitro synergy of polymyxin B-based combinations against polymyxin B -resistant gram-negative bacilli.",
"datePublished": "2022-04-07",
"url": "https://recherchemedicale.com/article/35398467",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.micpath.2022.105517"
}
},
{
"@type": "ScholarlyArticle",
"name": "Polymyxin B-induced Bartter syndrome.",
"datePublished": "2024-05-03",
"url": "https://recherchemedicale.com/article/38702070",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2023-255242"
}
},
{
"@type": "ScholarlyArticle",
"name": "Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins.",
"datePublished": "2024-08-26",
"url": "https://recherchemedicale.com/article/39187812",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12879-024-09759-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "MvfR Controls Tolerance to Polymyxin B by Regulating",
"datePublished": "2023-04-11",
"url": "https://recherchemedicale.com/article/37039709",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/spectrum.00426-23"
}
},
{
"@type": "ScholarlyArticle",
"name": "Population pharmacokinetics of polymyxin B in patients with liver dysfunction.",
"datePublished": "2023-08-08",
"url": "https://recherchemedicale.com/article/37461291",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bcp.15855"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://recherchemedicale.com/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://recherchemedicale.com/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://recherchemedicale.com/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Perforines",
"item": "https://recherchemedicale.com/mesh/D052899"
},
{
"@type": "ListItem",
"position": 6,
"name": "Peptides antimicrobiens cationiques",
"item": "https://recherchemedicale.com/mesh/D023181"
},
{
"@type": "ListItem",
"position": 7,
"name": "Polymyxines",
"item": "https://recherchemedicale.com/mesh/D011113"
},
{
"@type": "ListItem",
"position": 8,
"name": "Polymyxine B",
"item": "https://recherchemedicale.com/mesh/D011112"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Polymyxine B - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Polymyxine B",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-02-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Polymyxine B",
"description": "Comment diagnostiquer une infection nécessitant la polymyxine B ?\nQuels tests sont utilisés pour évaluer l'efficacité de la polymyxine B ?\nQuels signes cliniques indiquent une infection grave ?\nLa polymyxine B est-elle utilisée pour toutes les infections ?\nQuels sont les critères d'hospitalisation pour une infection ?",
"url": "https://recherchemedicale.com/mesh/D011112#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Polymyxine B",
"description": "Quels symptômes indiquent une infection bactérienne ?\nLa polymyxine B peut-elle provoquer des effets secondaires ?\nQuels signes d'allergie à la polymyxine B ?\nComment reconnaître une infection résistante ?\nQuels symptômes d'une infection urinaire ?",
"url": "https://recherchemedicale.com/mesh/D011112#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Polymyxine B",
"description": "Comment prévenir les infections résistantes ?\nQuelles sont les bonnes pratiques d'hygiène ?\nLes vaccins aident-ils à prévenir les infections ?\nComment éviter la transmission des bactéries ?\nLes antibiotiques en prévention sont-ils recommandés ?",
"url": "https://recherchemedicale.com/mesh/D011112#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Polymyxine B",
"description": "Comment la polymyxine B est-elle administrée ?\nQuels sont les traitements alternatifs à la polymyxine B ?\nLa polymyxine B est-elle efficace contre toutes les bactéries ?\nQuels sont les protocoles de traitement avec la polymyxine B ?\nPeut-on combiner la polymyxine B avec d'autres antibiotiques ?",
"url": "https://recherchemedicale.com/mesh/D011112#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Polymyxine B",
"description": "Quelles sont les complications possibles de la polymyxine B ?\nComment gérer la néphrotoxicité ?\nQuels sont les signes de neurotoxicité ?\nLa polymyxine B peut-elle causer des infections secondaires ?\nQuels patients sont à risque de complications ?",
"url": "https://recherchemedicale.com/mesh/D011112#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Polymyxine B",
"description": "Quels facteurs augmentent le risque d'infections résistantes ?\nLes personnes âgées sont-elles plus à risque ?\nLes patients immunodéprimés sont-ils à risque ?\nComment le diabète influence-t-il le risque d'infection ?\nLes interventions chirurgicales augmentent-elles le risque d'infection ?",
"url": "https://recherchemedicale.com/mesh/D011112#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection nécessitant la polymyxine B ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des cultures bactériennes et des tests de sensibilité aux antibiotiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité de la polymyxine B ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de sensibilité in vitro et des analyses cliniques des symptômes sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une infection grave ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre élevée, tachycardie, hypotension et signes de septicémie peuvent indiquer une infection grave."
}
},
{
"@type": "Question",
"name": "La polymyxine B est-elle utilisée pour toutes les infections ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle est principalement réservée aux infections causées par des bactéries Gram-négatives résistantes."
}
},
{
"@type": "Question",
"name": "Quels sont les critères d'hospitalisation pour une infection ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la gravité des symptômes, l'âge et les comorbidités du patient."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une infection bactérienne ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, frissons, douleur localisée et fatigue sont des symptômes courants d'infection."
}
},
{
"@type": "Question",
"name": "La polymyxine B peut-elle provoquer des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme néphrotoxicité et neurotoxicité peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels signes d'allergie à la polymyxine B ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou difficultés respiratoires peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection résistante ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une infection persistante malgré un traitement antibiotique peut indiquer une résistance."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une infection urinaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Brûlures à la miction, besoin fréquent d'uriner et douleurs pelviennes sont typiques."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections résistantes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une utilisation prudente des antibiotiques et des mesures d'hygiène adéquates sont essentielles."
}
},
{
"@type": "Question",
"name": "Quelles sont les bonnes pratiques d'hygiène ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains régulièrement, désinfecter les surfaces et éviter le contact avec des malades."
}
},
{
"@type": "Question",
"name": "Les vaccins aident-ils à prévenir les infections ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains vaccins peuvent prévenir des infections bactériennes spécifiques et réduire les résistances."
}
},
{
"@type": "Question",
"name": "Comment éviter la transmission des bactéries ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le partage d'objets personnels et pratiquer une bonne hygiène respiratoire."
}
},
{
"@type": "Question",
"name": "Les antibiotiques en prévention sont-ils recommandés ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation préventive d'antibiotiques n'est généralement pas recommandée sauf dans certains cas spécifiques."
}
},
{
"@type": "Question",
"name": "Comment la polymyxine B est-elle administrée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement administrée par voie intraveineuse ou intramusculaire selon l'infection."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements alternatifs à la polymyxine B ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "D'autres antibiotiques comme les carbapénèmes peuvent être utilisés selon la sensibilité."
}
},
{
"@type": "Question",
"name": "La polymyxine B est-elle efficace contre toutes les bactéries ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle est principalement efficace contre certaines bactéries Gram-négatives résistantes."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de traitement avec la polymyxine B ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protocoles varient selon l'infection, mais incluent souvent des doses ajustées selon la fonction rénale."
}
},
{
"@type": "Question",
"name": "Peut-on combiner la polymyxine B avec d'autres antibiotiques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des combinaisons peuvent être utilisées pour élargir le spectre d'action contre les infections."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la polymyxine B ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la néphrotoxicité, la neurotoxicité et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment gérer la néphrotoxicité ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut la surveillance de la fonction rénale et l'ajustement des doses si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels sont les signes de neurotoxicité ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des vertiges, des engourdissements ou des convulsions peuvent indiquer une neurotoxicité."
}
},
{
"@type": "Question",
"name": "La polymyxine B peut-elle causer des infections secondaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation d'antibiotiques peut perturber la flore bactérienne et entraîner des infections secondaires."
}
},
{
"@type": "Question",
"name": "Quels patients sont à risque de complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des maladies rénales préexistantes ou ceux recevant d'autres médicaments néphrotoxiques sont à risque."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'infections résistantes ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation excessive d'antibiotiques, l'hospitalisation prolongée et les soins intensifs augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un système immunitaire affaibli, ce qui les rend plus vulnérables."
}
},
{
"@type": "Question",
"name": "Les patients immunodéprimés sont-ils à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients immunodéprimés sont plus susceptibles de développer des infections graves."
}
},
{
"@type": "Question",
"name": "Comment le diabète influence-t-il le risque d'infection ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diabète peut altérer la réponse immunitaire, augmentant ainsi le risque d'infections bactériennes."
}
},
{
"@type": "Question",
"name": "Les interventions chirurgicales augmentent-elles le risque d'infection ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interventions chirurgicales peuvent introduire des bactéries et augmenter le risque d'infection."
}
}
]
}
]
}
The Third Hospital of Changsha, Changsha, Hunan, PR China; Institute of Clinical Application of Antibiotics, Changsha, Hunan, PR China. Electronic address: xin-li@cssdsyy.com.
Monash Biomedicine Discovery Institute, Department of Microbiology, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia Jian.Li@monash.edu Tony.Velkov@unimelb.edu.au.
Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia Jian.Li@monash.edu Tony.Velkov@unimelb.edu.au.
Monash Biomedicine Discovery Institute, Department of Microbiology, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia.
Monash Biomedicine Discovery Institute, Department of Microbiology, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
Department of Clinical Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200082, China. wzjxyfy@163.com.
Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200082, China. wzjxyfy@163.com.
Key Laboratory of Veterinary Chemical Drugs and Pharmaceutics, Ministry of Agriculture and Rural Affairs, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
National Clinical Research Center for Respiratory Diseases, Clinical Center for Pulmonary Infections, China-Japan Friendship Hospital, Capital Medical University, Beijing, China.
Department of Respiratory and Critical Care Medicine, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
This study aimed to evaluate the in vitro synergy of polymyxin B (PMB) combined with 11 other antibiotics against PMB-resistant gram-negative bacilli (GNBs)....
Thirty-six clinical isolates of PMB-resistant GNBs were used. The MICs of all the antimicrobials tested were determined by the broth microdilution method and the checkerboard assay method. Carbapenema...
Among the 36 strains, 15 harboured the carbapenemase gene, and blaKPC was the predominant carbapenemase. The resistance rates of the 36 strains to tigecycline, meropenem, ceftazidime, and cefepime wer...
PMB in combination with tigecycline and avibactam-based BL-BLIs could be a potential clinical option for clinical treatment of infections caused by PMB -resistant GNBs....
Bartter syndrome is a genetic disorder characterised by chloride-unresponsive metabolic alkalosis, hypokalaemia, hypomagnesaemia and hypercalciuria. While it commonly presents antenatally or in early ...
The study aimed to compare polymyxin B with colistimethate sodium (CMS) regarding neurotoxicity, nephrotoxicity and 30-day mortality in patients with MDR Gram-negatives....
All adult patients who received polymyxin B or CMS for at least 24 h for the treatment of MDR microorganisms were evaluated retrospectively....
Among 413 initially screened patients, 147 patients who were conscious and able to express their symptoms were included in the neurotoxicity analysis. 13 of 77 patients with polymyxin B and 1 of 70 wi...
Neurotoxicity is a relatively common adverse event that leads to drug withdrawal during polymyxins, particularly polymyxin B. Nephrotoxicity is very common during polymyxin therapy and the two polymyx...
Polymyxins are currently the last-resort antibiotics for the treatment of multidrug-resistant Gram-negative bacterial infections. To expand the understanding of the intrinsic resistance mechanism agai...
Polymyxin B (PMB) is widely used to treat infections caused by multidrug-resistant Gram-negative pathogens. Currently, the pharmacokinetic data of PMB in patients with liver dysfunction are limited. T...
We conducted a retrospective pharmacokinetic study involving 136 adults with different levels of liver function. Nonlinear mixed effects modelling was used to develop a PopPK model of PMB. Monte Carlo...
PMB pharmacokinetic analyses included 401 steady-state concentrations in 136 adult patients. A one-compartment pharmacokinetic model with first-order absorption and elimination was used to describe th...
This study provided PMB pharmacokinetic information for patients with liver dysfunction. Patients with renal and liver dysfunctions may not require an initial dose adjustment. Rather than PopPK-guided...
Determination of sensitivity to polymyxins has always been a challenge, especially in clinical laboratory routines. This study evaluated two rapid, simple, and inexpensive phenotypic methods to test p...
The antibacterial activity of graphene oxide (GO) has been widely explored and tested against various pathogenic bacterial strains. Although antimicrobial activity of GO against planktonic bacterial c...
The antibacterial effects of the resulting materials were examined by evaluating minimum inhibitory concentration, minimum bactericidal concentration, time kill assay, live/dead viability staining and...
PMB adsorption significantly enhanced the bacteriostatic and bactericidal activity of GO against both planktonic cells and bacterial cells in biofilms. Furthermore, the coatings of PMB-adsorbed GO app...
The emergence and growth of bacterial resistance to antibiotics poses an enormous threat to humanity in the future. In this regard, the discovery of new antibiotics and the improvement of existing one...
We investigated the in vitro antibacterial activity of the combination rifampicin (RIF) + polymyxin B (PB) against extensively drug-resistant (XDR) Klebsiella pneumoniae isolates. We evaluated clinica...